Blueprint Medicines (BPMC) PT Raised to $92 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 15 | New: 36
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 15 | New: 36
Join SI Premium – FREE
Morgan Stanley analyst David Lebowitz raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $92.00 (from $88.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Marvell (MRVL) PT Raised to $225 at TD Cowen
- DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss
- Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $42 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
